Henry Schein (NASDAQ:HSIC) Stock Rating Lowered by Wall Street Zen

Henry Schein (NASDAQ:HSIC) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Sunday.

A number of other research analysts have also recently commented on HSIC. Citigroup reiterated a “buy” rating and issued a $112.00 price target (up from $100.00) on shares of Henry Schein in a research note on Wednesday, August 5th. Morgan Stanley restated an “underweight” rating and set a $64.00 price objective (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Stifel Nicolaus set a $95.00 target price on Henry Schein in a report on Wednesday, August 5th. Mizuho dropped their target price on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Finally, BMO Capital Markets initiated coverage on Henry Schein in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $92.27.

Henry Schein Stock Down 0.1%

Shares of NASDAQ HSIC opened at $88.08 on Friday. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60. The company has a market cap of $9.82 billion, a price-to-earnings ratio of 25.68, a PEG ratio of 1.68 and a beta of 0.80. Henry Schein has a 12 month low of $61.94 and a 12 month high of $92.18. The stock has a 50-day moving average price of $83.72 and a two-hundred day moving average price of $78.74.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $0.03. The company had revenue of $3.46 billion for the quarter, compared to the consensus estimate of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period last year, the company posted $1.10 EPS. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. As a group, analysts forecast that Henry Schein will post 5.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Invesco Ltd. increased its stake in shares of Henry Schein by 4.1% in the third quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock valued at $314,043,000 after buying an additional 184,763 shares during the period. Southpoint Capital Advisors LP lifted its stake in shares of Henry Schein by 28.0% in the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock worth $235,840,000 after acquiring an additional 700,000 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Henry Schein by 2.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company’s stock valued at $211,734,000 after acquiring an additional 56,687 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Henry Schein by 11.3% in the third quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock valued at $167,453,000 after acquiring an additional 256,156 shares during the last quarter. Finally, Bank of Montreal Can increased its position in Henry Schein by 3,655.7% during the 4th quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after purchasing an additional 2,087,666 shares during the period. 96.62% of the stock is owned by institutional investors and hedge funds.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.